|
2017 Conference Publication The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic LeukaemiaTobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. |
|
2016 Conference Publication Complete responders to anti-PD1 antibodies. What happens when we stop?Atkinson, V. G. and Ladwa, R. (2016). Complete responders to anti-PD1 antibodies. What happens when we stop?. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.11 |
|
2016 Conference Publication Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access programLadwa, R., Andelkovic, V. and Atkinson, V. (2016). Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program. Implementation + Innovation in Immunotherapy, Gold Coast, QLD, Australia, 3-5 August 2016. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12542 |
|
2015 Conference Publication Pembrolizumab for metastatic melanoma - one year results of named patient access programAtkinson, Victoria G., Andelkovic, Vladimir and Gunawan, Benjamin (2015). Pembrolizumab for metastatic melanoma - one year results of named patient access program. COSA’s 42nd Annual Scientific Meeting. Rare Cancers: Common Goals, Hobart, TAS, Australia, 17-19 November 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12432_2 |
|
2015 Conference Publication Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapyPrivthviraj, Prashanth, McArthur, Grant, Atkinson, Victoria, Parente, Phillip, Andrews, Miles Cameron, Parakh, Sagun, Cebon, Jonathon and Klein, Oliver (2015). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2015 Conference Publication Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.Larkin, James M. G., Yan, Yibing, McArthur, Grant A., Ascierto, Paolo Antonio, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev V., Stroyakovskiy, Daniil, Thomas, Luc, De La Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Wongchenko, Matthew, Rooney, Isabelle Anne, Chang, Ilsung, Hack, Stephen Paul, Dreno, Brigitte and Ribas, Antoni (2015). Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2015 Conference Publication Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066)Long, Georgina V., Atkinson, Victoria, Ascierto, Paolo Antion, Robert, Caroline, Hassel, Jessica Cecile, Rutkowski, Piotr, Savage, Kerry, Taylor, Fiona, Coon, Cheryl, Gilloteau, Isabelle, Dasanti, Homa, Waxman, Ian and Pickar Abernethy, Amy (2015). Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066). American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2014 Conference Publication Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE StudyMartin-Algarra, Salvador, Cebon, Jonathan, Neyns, Bart, Brown, Ewan, Puertolas, Teresa, Garcia, Yolanda, Atkinson, Victoria, Crown, John, Lau, Mike, Dalland, Lindi, Stein, Dara, Payne, Krista, Aktan, Gursel, Jobanputra, Minesh, Queirolo, Paola and Millward, Michael (2014). Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study. Society for Melanoma Research, Zurich, Switzerland, November 2014. Hoboken, NJ United States: Wiley-Blackwell Publishing. doi: 10.1111/pcmr.12317 |
|
2013 Conference Publication Single institution experience of Hyperthermic Intraperitoneal ChemotherapyXu, Wen, Sparks, David, Atkinson, Victoria, Joubert, Warren, Lutton, Nicholas and Meade, Brian (2013). Single institution experience of Hyperthermic Intraperitoneal Chemotherapy. Annual Scientific Meeting of Medical Oncology Group of Australia, Melbourme, Australia, August 2013. |
|
2013 Conference Publication Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013Dzienis, Marcin Radoslaw and Atkinson, Victoria (2013). Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013. American Society of Clinical Oncology Annual Meeting, 2013, Chicago, IL United States, 31 May - 3 June 2013. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2012 Conference Publication Retrospective review of patients managed with chemotherapy for metastatic colorectal cancer at the Princess Alexandra HospitalRyan, C., Atkinson, V. and Klein, K. (2012). Retrospective review of patients managed with chemotherapy for metastatic colorectal cancer at the Princess Alexandra Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Queensland, Australia, 8 – 10 August 2012. Oxford, United Kingdom: Wiley-Blackwell Publishing. |
|
2011 Conference Publication Single Institution Experience of the Stupp Protocol in Management of Glioblastoma MultiformeCaird, Susan and Atkinson, Victoria (2011). Single Institution Experience of the Stupp Protocol in Management of Glioblastoma Multiforme. Annual Scientific Meeting of Medical Oncology Group of Australia, Adelaide, SA Australia, 10-12 August 2011. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/j.1743-7563.2011.01417.x |
